Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease

Show other versions (1)

Bibliographic Details
Main Author:	Chris Terpening
Format:	Article
Language:	English
Published:	SAGE Publishing 2010-12-01
Series:	Clinical Medicine Insights: Cardiology
Online Access:	http://www.la-press.com/clopidogrel-a-pharmacogenomic-perspective-on-its-use-in-coronary-arter-a2383

Similar Items

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease
by: Chris Terpening
Published: (2010-01-01)

Pharmacogenomics and genetic risk factors of coronary artery disease
by: Duan, Qingling.
Published: (2008)

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
by: Rakesh K Sharma, et al.
Published: (2009-11-01)

The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]
by: Mesana Thierry G, et al.
Published: (2005-10-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
by: Kisor DF, et al.
Published: (2021-05-01)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
by: Ying Yao, et al.
Published: (2019-10-01)

The expression profile of platelet‐derived miRNA in coronary artery disease patients with clopidogrel resistance
by: Shaoyi Lin, et al.
Published: (2021-04-01)

Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting
by: Hyoung Woo Chang, et al.
Published: (2019-01-01)

Risk reduction with clopidogrel in the management of peripheral arterial disease
by: Keshav R Nayak, et al.
Published: (2007-07-01)

Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure
by: Neil A. Smart, et al.
Published: (2011-06-01)

Bucindolol: A Pharmacogenomic Perspective on its Use in Chronic Heart Failure
by: Neil A. Smart, et al.
Published: (2011-01-01)

A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease
by: Zhaojian Zhang, et al.
Published: (2019-01-01)

Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease
by: İbrahim Halil Tanboğa, et al.
Published: (2013-07-01)

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention
by: Jun Pang, et al.
Published: (2019-06-01)

Coronary artery bypass grafting on clopidogrel or ticagrelor therapy: interval of discontinuation and risk of bleeding
by: Paolo Nardi, et al.
Published: (2020-01-01)

Predictors of premature clopidogrel discontinuation within 30 days of successful coronary artery stenting
by: Çayan Cakir, et al.
Published: (2018-01-01)

Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel
by: Alexander Kurian S, et al.
Published: (2003-05-01)

Clopidogrel responsiveness in chronic kidney disease patients with acute coronary syndrome
by: Hale Ünal Aksu, et al.
Published: (2014-03-01)

Clopidogrel resistance in patients with acute coronary syndrome
by: N S Frolova, et al.
Published: (2010-08-01)

Association of N6AMT1 rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease
by: He Li, et al.
Published: (2018-09-01)

Pharmacogenomics of Cardiovascular Pharmacology: Pharmacogenomic Network of Cardiovascular Disease Models
by: Toshio Tanaka, et al.
Published: (2008-01-01)

ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.
by: Jia Su, et al.
Published: (2012-01-01)

Association of P2Y12 Gene Promoter DNA Methylation with the Risk of Clopidogrel Resistance in Coronary Artery Disease Patients
by: Jia Su, et al.
Published: (2014-01-01)

Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease
by: Wanbing He, et al.
Published: (2021-02-01)

Determinants to optimize response to clopidogrel in acute coronary syndrome
by: Betti Giusti, et al.
Published: (2010-04-01)

Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
by: Arijit Dasgupta, et al.
Published: (2009-03-01)

Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery
by: S K Zyryanov, et al.
Published: (2016-09-01)

The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study
by: Ali Reza Khosravi, et al.
Published: (2011-01-01)

Pharmacogenomics In Pharmacy Practice: Current Perspectives
by: Elewa H, et al.
Published: (2019-11-01)

Pharmacogenomics in Parkinson’s disease: which perspective for developing a personalized medicine?
by: Cinzia Ciccacci, et al.
Published: (2019-01-01)

Pharmacogenetics, pharmacogenomics and airway disease
by: Hall Ian P
Published: (2001-11-01)

Effects of clopidogrel on coagulation function, antioxidant and related cytokines in patients with coronary heart disease
by: Xu-Hui Liu, et al.
Published: (2018-09-01)

Adoption of Pharmacogenomic Testing: A Marketing Perspective
by: Margarita-Ioanna Koufaki, et al.
Published: (2021-09-01)

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
by: Parag Admane, et al.
Published: (2013-03-01)

Clopidogrel therapy effects on cell hemostasis in acute coronary syndrome
by: R. A. Rakhimova, et al.
Published: (2008-12-01)

Assessing the efficacy of aspirin and clopidogrel in patients with acute coronary syndromes
by: Varadharajan, Vatchsala Sree
Published: (2018)

Clinical use of pharmacogenomics
by: Telenti Amalio
Published: (2012-05-01)

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
by: Damrus Tresukosol, et al.
Published: (2014-01-01)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
by: Nicholas B Norgard, et al.
Published: (2009-10-01)

Cannot write session to /tmp/vufind_sessions/sess_2nsjeqg9bpakj1skas7k989uv6